Ultrasonography-Guided Core Needle Biopsy in the Diagnostic Pathway of Pelvic Tumors - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Core Needle Biopsy Guided by Ultrasonography in the Evaluation of Pelvic Tumors

  • By

  • Stefan Timmerman

  • Cristina Taliento

  • Jolien Haesen

  • Susan Dababou

  • Federica Pozzati

  • Lorena Quagliozzi

  • Francesca Moro

  • Floriana Mascilini

  • Antonia Testa

  • Filip Frühauf

  • Roman Kocian

  • Daniela Fischerova

  • Elisabeth Epstein

  • Robert Fruscio

  • Ashleigh Ledger

  • Thierry Van den Bosch

  • Wouter Froyman

  • August 14, 2026

Share

  • 1

    Core needle biopsy guided by ultrasonography is crucial for diagnosing malignant pelvic lesions and informing treatment strategies.

  • 2

    This study assesses the safety and diagnostic adequacy of core needle biopsies in patients with pelvic tumors across multiple centers.

  • 3

    Ultrasonography-guided biopsies provide high diagnostic accuracy and low complication rates for abdominal and pelvic lesions.

  • 4

    Inclusion criteria for biopsies required safe accessibility of lesions, while exclusion criteria included age under 18 and certain medical conditions.

  • 5

    Biopsies were performed using various techniques, with local anesthesia applied in percutaneous approaches but not in transvaginal or transrectal methods.

Original Source(s)

Ultrasonography-Guided Core Needle Biopsy in the Diagnostic Pathway of Pelvic Tumors

  • by Stefan Timmerman, Cristina Taliento, Jolien Haesen, Susan Dababou, Federica Pozzati, Lorena Quagliozzi, Francesca Moro, Floriana Mascilini, Antonia Testa, Filip Frühauf, Roman Kocian, Daniela Fischerova, Elisabeth Epstein, Robert Fruscio, Ashleigh Ledger, Thierry Van den Bosch, Wouter Froyman

  • August 14, 2026

Related Content

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

  • by

  • September 15, 2026

  • 3 min
AI-Designed Binder Improves CAR T Cell Activity in Mice

Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

  • September 15, 2026

  • 3 min